X did not respond to a request for comment. In its privacy policy, the company has said it will not sell user data to a third ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Voyager Therapeutics Inc (VYGR) reports a robust financial runway and advances in Alzheimer's research, despite challenges in ...

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...

Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track ...

SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, newly appointed Donghyeon Kim, who is currently CTO (Chief Technology ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Discover whether it's possible to have mixed dementia, specifically a combination of Alzheimer's and Lewy body dementia. This ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...